On November 1, 2023, VYNE Therapeutics Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.89 USD | +2.12% | 0.00% | +24.03% |
May. 09 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
May. 09 | VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.03% | 40.75M | |
+31.47% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.13% | 239B | |
+9.89% | 210B | |
-7.24% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors